The role and efficacy of Nilotinib

Nilotinib (Nilotinib) is a cancer drug that interferes with the growth and spread of cancer cells in the body. Nilotinib is used to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and is available in adults and children at least 1 year old. Nilotinib is usually used after other drugs have failed.

Chronic myelogenous leukemia (CML) is a clonal disease of hematopoietic stem cells associated with a specific chromosomal translocation leading to the Philadelphia (Ph) chromosome. Fusion of the gene thus formed with BCR-ABL1 results in constitutive expression of the BCR-ABL1 kinase, leading to the manifestations of CML. Nilotinib is a second-generation oral TKI initially used to treat CML patients who are resistant or intolerant to imatinib. Nilotinib is effective and well tolerated in these patients. Among patients with chronic-phase CML (CML-CP) who received nilotinib as second-line therapy, 59% achieved major cytogenetic response (MCyR) and 44% achieved complete cytogenetic response (CCyR), with an estimated overall survival (OS) rate of approximately 80% at 48 months.

The original drug Nilotinib is marketed in China under the name Nilotinib and is covered by medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of 150mg*120 capsules per box may be around 9,000 yuan. The Indian version of Nilotinib is available overseas. The price of Nilotinib's original drug, 150mg*28 capsules per box, may be around RMB 1,000 (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. Currently, there is no generic version of Nilotinib produced and launched. For more drug information and specific prices, please consult Yaode Medical Consultants.